Literature DB >> 26216631

Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.

Katherine H Parker1, Daniel W Beury1, Suzanne Ostrand-Rosenberg2.   

Abstract

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that suppress innate and adaptive immunity. MDSCs are present in many disease settings; however, in cancer, they are a major obstacle for both natural antitumor immunity and immunotherapy. Tumor and host cells in the tumor microenvironment (TME) produce a myriad of pro-inflammatory mediators that activate MDSCs and drive their accumulation and suppressive activity. MDSCs utilize a variety of mechanisms to suppress T cell activation, induce other immune-suppressive cell populations, regulate inflammation in the TME, and promote the switching of the immune system to one that tolerates and enhances tumor growth. Because MDSCs are present in most cancer patients and are potent immune-suppressive cells, MDSCs have been the focus of intense research in recent years. This review describes the history and identification of MDSCs, the role of inflammation and intracellular signaling events governing MDSC accumulation and suppressive activity, immune-suppressive mechanisms utilized by MDSCs, and recent therapeutics that target MDSCs to enhance antitumor immunity.
© 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cytokines; Immature myeloid cells; Immunotherapy; Inflammation; Macrophages; Myeloid cell cross talk; STAT3; Tumor-induced immune suppression; Tumor-infiltrating lymphocytes; cEBPbeta

Mesh:

Year:  2015        PMID: 26216631      PMCID: PMC4662416          DOI: 10.1016/bs.acr.2015.04.002

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  193 in total

1.  IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function.

Authors:  Moshe Elkabets; Vera S G Ribeiro; Charles A Dinarello; Suzanne Ostrand-Rosenberg; James P Di Santo; Ron N Apte; Christian A J Vosshenrich
Journal:  Eur J Immunol       Date:  2010-12       Impact factor: 5.532

Review 2.  Myeloid-derived suppressor cells in cancer patients: a clinical perspective.

Authors:  Alberto J Montero; Claudia Marcela Diaz-Montero; Christos E Kyriakopoulos; Vincenzo Bronte; Susanna Mandruzzato
Journal:  J Immunother       Date:  2012 Feb-Mar       Impact factor: 4.456

3.  Dopamine inhibits the function of Gr-1+CD115+ myeloid-derived suppressor cells through D1-like receptors and enhances anti-tumor immunity.

Authors:  Jin Wu; Ruihua Zhang; Ning Tang; Zizhen Gong; Jiefei Zhou; Yingwei Chen; Kang Chen; Wei Cai
Journal:  J Leukoc Biol       Date:  2014-10-23       Impact factor: 4.962

4.  Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer.

Authors:  Ping-Ying Pan; Ge Ma; Kaare J Weber; Junko Ozao-Choy; George Wang; Bingjiao Yin; Celia M Divino; Shu-Hsia Chen
Journal:  Cancer Res       Date:  2009-12-08       Impact factor: 12.701

5.  Passive transfer of tumour-derived MDSCs inhibits asthma-related airway inflammation.

Authors:  C Song; Y Yuan; X-M Wang; D Li; G-M Zhang; B Huang; Z-H Feng
Journal:  Scand J Immunol       Date:  2014-02       Impact factor: 3.487

6.  Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL.

Authors:  Pratima Sinha; Olesya Chornoguz; Virginia K Clements; Konstantin A Artemenko; Roman A Zubarev; Suzanne Ostrand-Rosenberg
Journal:  Blood       Date:  2011-03-30       Impact factor: 22.113

7.  Phosphatidylserine-targeting antibody induces M1 macrophage polarization and promotes myeloid-derived suppressor cell differentiation.

Authors:  Yi Yin; Xianming Huang; Kristi D Lynn; Philip E Thorpe
Journal:  Cancer Immunol Res       Date:  2013-08-19       Impact factor: 11.151

8.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.

Authors:  C Marcela Diaz-Montero; Mohamed Labib Salem; Michael I Nishimura; Elizabeth Garrett-Mayer; David J Cole; Alberto J Montero
Journal:  Cancer Immunol Immunother       Date:  2008-04-30       Impact factor: 6.968

9.  CD11b+Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis.

Authors:  Bing Zhu; Yoshio Bando; Sheng Xiao; Kaiyong Yang; Ana C Anderson; Vijay K Kuchroo; Samia J Khoury
Journal:  J Immunol       Date:  2007-10-15       Impact factor: 5.422

Review 10.  Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the ugly.

Authors:  Paolo Serafini
Journal:  Immunol Res       Date:  2013-12       Impact factor: 4.505

View more
  203 in total

Review 1.  The Immune System and the Role of Inflammation in Perinatal Depression.

Authors:  Philippe Leff-Gelman; Ismael Mancilla-Herrera; Mónica Flores-Ramos; Carlos Cruz-Fuentes; Juan Pablo Reyes-Grajeda; María Del Pilar García-Cuétara; Marielle Danitza Bugnot-Pérez; David Ellioth Pulido-Ascencio
Journal:  Neurosci Bull       Date:  2016-07-18       Impact factor: 5.203

Review 2.  Myeloid Cells and Chronic Liver Disease: a Comprehensive Review.

Authors:  Min Lian; Carlo Selmi; M Eric Gershwin; Xiong Ma
Journal:  Clin Rev Allergy Immunol       Date:  2018-04       Impact factor: 8.667

3.  Myeloid-derived suppressor cells mediate tolerance induction in autoimmune disease.

Authors:  Anja Wegner; Johan Verhagen; David C Wraith
Journal:  Immunology       Date:  2017-03-02       Impact factor: 7.397

4.  Targeting Autocrine CCL5-CCR5 Axis Reprograms Immunosuppressive Myeloid Cells and Reinvigorates Antitumor Immunity.

Authors:  Yi Ban; Junhua Mai; Xin Li; Marisa Mitchell-Flack; Tuo Zhang; Lixing Zhang; Lotfi Chouchane; Mauro Ferrari; Haifa Shen; Xiaojing Ma
Journal:  Cancer Res       Date:  2017-04-17       Impact factor: 12.701

5.  Myeloid-derived suppressor cell, arginase-1, IL-17 and cl-CD95L: an explosive cocktail in lupus?

Authors:  Robin J Flynn; Patrick Legembre
Journal:  Ann Transl Med       Date:  2016-12

6.  Exosomes Produced by Mesenchymal Stem Cells Drive Differentiation of Myeloid Cells into Immunosuppressive M2-Polarized Macrophages in Breast Cancer.

Authors:  Subir Biswas; Gunjan Mandal; Sougata Roy Chowdhury; Suman Purohit; Kyle K Payne; Carmen Anadon; Arnab Gupta; Patricia Swanson; Xiaoqing Yu; José R Conejo-Garcia; Arindam Bhattacharyya
Journal:  J Immunol       Date:  2019-11-08       Impact factor: 5.422

7.  IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells.

Authors:  Wei Xiao; John D Klement; Chunwan Lu; Mohammed L Ibrahim; Kebin Liu
Journal:  J Immunol       Date:  2018-05-11       Impact factor: 5.422

Review 8.  The pan-therapeutic resistance of disseminated tumor cells: Role of phenotypic plasticity and the metastatic microenvironment.

Authors:  Bo Ma; Alan Wells; Amanda M Clark
Journal:  Semin Cancer Biol       Date:  2019-07-31       Impact factor: 15.707

9.  Top-Down Proteomic Characterization of Truncated Proteoforms.

Authors:  Dapeng Chen; Lucia Geis-Asteggiante; Fabio P Gomes; Suzanne Ostrand-Rosenberg; Catherine Fenselau
Journal:  J Proteome Res       Date:  2019-10-03       Impact factor: 4.466

10.  Potentiating cancer vaccine efficacy in liver cancer.

Authors:  Maria Tagliamonte; Annacarmen Petrizzo; Angela Mauriello; Maria Lina Tornesello; Franco M Buonaguro; Luigi Buonaguro
Journal:  Oncoimmunology       Date:  2018-07-23       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.